Advertisement
Screener

Acumen Pharmaceuticals, Inc. (ABOS) Weighted Average Number of Shares Outstanding, Basic and Diluted

2.8 / 5 stars · 68/120 Roast Me

Acumen Pharmaceuticals, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted

Acumen Pharmaceuticals, Inc. (ABOS) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 40.47 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-16.

Discontinued › Income Statement › Earnings Per Share

us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-16

  • Acumen Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 40.47M shares, a 9556.63% increase year-over-year.
  • Acumen Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 40.70M shares, a 9609.82% increase year-over-year.
  • Acumen Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 38.27M shares, a 9030.14% increase year-over-year.
  • Acumen Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 432.32K shares, a 3.15% increase year-over-year.
  • Acumen Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 20.06M shares, a 4685.58% increase from fiscal 2020.
  • Acumen Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 419.12K shares.
Period endWeighted Average Number of Shares Outstanding, Basic and Diluted 3 monthWeighted Average Number of Shares Outstanding, Basic and Diluted 6 monthWeighted Average Number of Shares Outstanding, Basic and Diluted 9 monthWeighted Average Number of Shares Outstanding, Basic and Diluted 12 month
2022-03-3140.47M shares
10-Q · filed 2022-05-16
40.58M shares
derived: average of 2 quarters · filed 2022-05-16
39.81M shares
derived: average of 3 quarters · filed 2022-05-16
29.97M shares
derived: average of 4 quarters · filed 2022-05-16
2021-12-3140.70M shares
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28
39.48M shares
derived: average of 2 quarters · filed 2022-03-28
26.47M shares
derived: average of 3 quarters · filed 2022-03-28
20.06M shares
10-K · filed 2022-03-28
2021-09-3038.27M shares
10-Q · filed 2021-11-15
19.35M shares
derived: average of 2 quarters · filed 2021-11-15
13.18M shares
10-Q · filed 2021-11-15
9.88M shares
derived: average of 4 quarters · filed 2022-05-16
2021-06-30432.32K shares
10-Q · filed 2021-08-16
425.76K shares
10-Q · filed 2021-08-16
423.52K shares
derived: average of 3 quarters · filed 2022-05-16
422.42K shares
derived: average of 4 quarters · filed 2022-05-16
2021-03-31419.12K shares
10-Q · filed 2022-05-16
419.12K shares
derived: average of 2 quarters · filed 2022-05-16
419.12K shares
derived: average of 3 quarters · filed 2022-05-16
419.12K shares
derived: average of 4 quarters · filed 2022-05-16
2020-12-31419.12K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28
419.12K shares
derived: average of 2 quarters · filed 2022-03-28
419.12K shares
derived: average of 3 quarters · filed 2022-03-28
419.12K shares
10-K · filed 2022-03-28
2020-09-30419.12K shares
10-Q · filed 2021-11-15
419.12K shares
derived: average of 2 quarters · filed 2021-11-15
419.12K shares
10-Q · filed 2021-11-15
2020-06-30419.12K shares
10-Q · filed 2021-08-16
419.12K shares
10-Q · filed 2021-08-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48